Biotechnology

BiomX

Zorronet Launches Mobile Command Control App

BiomX Inc. Acquires Zorronet to Enter Defense and Security Field

BiomX released FY2025 Annual Earnings on February 19, 2026 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD 0 (forecast USD -20.35)

BiomX released FY2025 Q4 earnings on February 19 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -6.6686 (forecast USD -5.06)

BiomX released FY2025 9 Months Earnings on November 12 Pre-Market (EST), with actual revenue of USD 0 and EPS of USD -0.8162

BiomX released FY2025 Q3 earnings on November 12 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -5.5463 (forecast USD -6.08)

BiomX to Release FY2025 Q3 Earnings on November 12 Pre-Market EST, Forecast EPS -0.32 USD

BiomX Inc. Receives Additional FDA Questions on BX004 Inhaler Device

BIOMX Provides BX004 Project Update and Receives Positive FDA Feedback

BiomX released FY2025 Semi-Annual Earnings on August 13 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -9.5494 (forecast USD -12.54)

BiomX released FY2025 Q2 earnings on August 13 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1928 (forecast USD -0.26)

BiomX to Release FY2025 Q2 Earnings on August 13 Pre-Market EST, Forecast Revenue USD 0, EPS USD -0.26

BiomX's BX004 clinical trial shows positive results

BiomX's Phage Therapy Platform Shows Early Results in Clinical Trials

BiomX Reports Positive Clinical Trial Progress for Phage Therapy

BiomX Inc. CEO to speak at Israel BioMed Conference

BiomX Inc. Q1 2025 Earnings Beat Expectations

HC Wainwright Maintains Buy Rating on BiomX and Adjusts Target Price

BiomX released FY2025 Q1 earnings on May 15 During-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -6.2987 (forecast USD -6.84)

BiomX Announces Positive Top-Line Results for BX211 Phase 2 Trial for Diabetic Foot Osteomyelitis

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Micware

Vida Global

MicroAlgo

MetaVia

Tradr 2X Long XNDU Daily ETF

PHGE

BiomX rose 22.54%; Immunovant rose 34.16%, with a trading volume of USD 318 million; Amgen fell 0.35%, with a trading volume of USD 300 million; HCW Biologics rose 178.30%, with a trading volume of USD 216 million; AbbVie fell 0.55%, with a market value of USD 375.5 billion

Price Alert

Immunovant

Amgen

Abbvie

U.S. stock market midday update: BiomX up 22.54% with increased trading volume, market sentiment is high but volatility should be monitored

LABU

SBIO

In Wednesday's pre-market session, Silexion Therapeutics surged 147.2% to $0.67, while Jupiter Neurosciences rose 106.25% to $0.66. Other gainers included BiomX (+41.76%), Immunovant (+28.18%), China SXT Pharmaceuticals (+12.9%), and OmniAb (+10.97%). Conversely, Annovis Bio fell 17.5% to $1.6, Virax Biolabs declined 17.49% to $0.25, and Sunshine Biopharma dropped 17.26% to $0.36. Wellgistics Health, Purple Biotech, and GlucoTrack also experienced declines.

benzinga_article

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares US Medical Devices

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Jupiter Neurosciences

China SXT Pharmaceuticals

OmniAb

Annovis Bio

Virax Biolabs

Sunshine Biopharma

Wellgistics Health

Purple Biotech

GlucoTrack

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM)

OMNIAB INC C/WTS (TO PUR COM)

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

CISS

BiomX pre-market rose 36.84%; C3is pre-market fell 12.47%; Micware pre-market rose 302.73%; Silexion Therapeutics pre-market rose 167.99%; GCL Global pre-market rose 77.37%

C3is

Pre-market hot trades in US stocks: BiomX up 36.84% in pre-market; C3is down 12.47% in pre-market

BiomX has announced a delay in filing its Quarterly Report for the period ended March 31, 2026, due to the need for additional time to compile information on significant transactions. The company is undergoing a strategic shift, including a new board and expansion into defense technology. BiomX reported $3.0 million from Series Y financing and $3.3 million from warrant exercises. The results for the quarter are expected to differ materially from the previous year due to operational changes and insolvency proceedings.

Tip Ranks

BiomX Delays Quarterly Report Amid Strategic Shift

IBBQ

ARKG

BiomX has undergone a strategic overhaul, exiting its legacy biotech operations and transitioning to a diversified defense technology platform. The company has replaced its management team and adopted an acquisition-led strategy, controlling three subsidiaries focused on defense technologies. Despite securing early revenue opportunities, BiomX faces risks including limited operating history, customer concentration, and regulatory challenges. The stock is rated as a Buy with a $26.00 price target, but analysts express concerns over financial performance and potential dilution risks.

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

Ark Genomic Revolution ETF

Elbit

Rafael-B

BiomX Reinvents Itself as Diversified Defense Technology Platform

BiomX pre-market up 8.90%; Abits pre-market up 41.44%; Everspin Technologies pre-market up 35.78%; Akanda pre-market up 34.11%

Abits

Everspin Tech

Akanda

Pre-market hot trades in US stocks: BiomX up 8.90% in pre-market, with clear capital flow, market sentiment triggers volatility attention

PHGE stock has given up its prior gain. BiomX shares were trading higher after the company announced the deployment of its Zorronet subsidiary in collaboration with Israel Railways.

Zorronet Delivers 98% Success in Israel Railways Pilot, Awarded Framework Supply Agreement for AI-Powered Detection Systems | PHGE Stock News

StockTitan

Zorronet Delivers 98% Success in Israel Railways Pilot, Awarded Framework Supply Agreement for AI-Powered Detection Systems | PHGE Stock News

BiomX Inc. (PHGE) has acquired a controlling interest in DFSL, an engineering company, to expand into the defense sector. The acquisition involves cash, an unsecured convertible note, and warrants at $12 per share. BiomX aims to integrate DFSL's technologies, including LADAR for real-time tracking, with its AI platform for improved detection and response. PHGE shares closed at $2.63, down 9%, but rose to $2.68 in overnight trading, up 1.90%.

nasdaq

BiomX Acquires DFSL To Expand Defense Portfolio

BiomX Accelerates Defense Technology Buildout with DFSL Acquisition | PHGE Stock News

BiomX Accelerates Defense Technology Buildout with DFSL Acquisition | PHGE Stock News

BiomX(PHGE.US)

U.S. stock market midday update: BiomX up 22.54% with increased trading volume, market sentiment is high but volatility should be monitored

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Pre-market hot trades in US stocks: BiomX up 36.84% in pre-market; C3is down 12.47% in pre-market

BiomX Delays Quarterly Report Amid Strategic Shift

BiomX Reinvents Itself as Diversified Defense Technology Platform

Pre-market hot trades in US stocks: BiomX up 8.90% in pre-market, with clear capital flow, market sentiment triggers volatility attention

PHGE stock has given up its prior gain. BiomX shares were trading higher after the company announced the deployment of its Zorronet subsidiary in collaboration with Israel Railways.

Zorronet Delivers 98% Success in Israel Railways Pilot, Awarded Framework Supply Agreement for AI-Powered Detection Systems | PHGE Stock News

BiomX Acquires DFSL To Expand Defense Portfolio

BiomX Accelerates Defense Technology Buildout with DFSL Acquisition | PHGE Stock News